Trial Profile
Retention Rates of Adalimumab, Etanercept and Infliximab as First and Second-Line Biotherapy in Patients With Rheumatoid Arthritis in Daily Practice
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Sep 2012
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary) ; Etanercept (Primary) ; Infliximab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms MAINTAIN
- Sponsors Pfizer
- 28 Sep 2012 New trial record